OSE Immunotherapeutics Stock price

Equities

OSE

FR0012127173

Biotechnology & Medical Research

Real-time Euronext Paris 11:23:47 2024-03-28 am EDT 5-day change 1st Jan Change
4.85 EUR -0.41% Intraday chart for OSE Immunotherapeutics +0.52% +13.32%
Sales 2023 2.23M 2.4M Sales 2024 * 23.87M 25.76M Capitalization 105M 113M
Net income 2023 -23M -24.83M Net income 2024 * -10M -10.79M EV / Sales 2023 36.2 x
Net Debt 2023 * 33.7M 36.38M Net Debt 2024 * 45.46M 49.07M EV / Sales 2024 * 6.31 x
P/E ratio 2023
-3.63 x
P/E ratio 2024 *
-10.5 x
Employees 62
Yield 2023 *
-
Yield 2024 *
-
Free-Float 82.37%
More Fundamentals * Assessed data
Dynamic Chart
OSE IMMUNOTHERAPEUTICS : Degroof Petercam reiterates buy recommendation CF
OSE Immuno: recruitment completed for UC trial CF
Ose Immunotherapeutics Sa Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative Colitis CI
Transcript : OSE Immunotherapeutics SA - Special Call
AbbVie Secures Rights to OSE Immunotherapeutics' Drug Candidate MT
OSE Immuno: share price soars following partnership with AbbVie CF
OSE Immunotherapeutics, AbbVie Partner on Chronic Inflammation Monoclonal Antibody MT
OSE Immuno: new positive phase 1/2 data CF
OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors CI
OSE Immuno: positive interim analysis of study data CF
OSE Immunotherapeutics SA and Nantes University Hospital Presents Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant CI
Ose Immunotherapeutics, GenDx to Co-develop Diagnostic Test Companion for Cancer Vaccine Trial MT
OSE Immuno: collaboration agreement with GenDx CF
OSE Immunotherapeutics SA Announces A Collaboration Agreement with Genome Diagnostics B.V. for the Development of A Companion Diagnostic for Epitope-Based Cancer Vaccine Candidate Tedopi®? CI
Ose Immunotherapeutics Sa Announces First Clinical Results for Bi 770371, A Novel Anti-Sirpa Monoclonal Antibody CI
More news

Latest transcript on OSE Immunotherapeutics

1 day-0.41%
1 week+0.52%
Current month+2.00%
1 month-3.19%
3 months+10.86%
6 months+14.39%
Current year+13.32%
More quotes
1 week
4.54
Extreme 4.54
4.96
1 month
4.41
Extreme 4.41
5.50
Current year
3.12
Extreme 3.115
6.00
1 year
2.71
Extreme 2.705
7.31
3 years
2.71
Extreme 2.705
13.68
5 years
2.71
Extreme 2.705
15.80
10 years
2.70
Extreme 2.7
15.80
More quotes
Managers TitleAgeSince
Founder 69 04-11-16
Chief Executive Officer 42 16-05-30
Director of Finance/CFO - 16-04-30
Members of the board TitleAgeSince
Founder 69 04-11-16
Director/Board Member 66 23-06-21
Director/Board Member 66 22-02-17
More insiders
Date Price Change Volume
24-03-28 4.85 -0.41% 87 449
24-03-27 4.87 -1.32% 55,662
24-03-26 4.935 +2.81% 87,850
24-03-25 4.8 0.00% 88,440
24-03-22 4.8 -0.52% 79,202

Real-time Euronext Paris, March 28, 2024 at 11:23 am EDT

More quotes
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I). Its well-balanced first-in-class clinical pipeline is as follows: - Tedopi® (immunotherapy activating tumor specific T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is the Company's most advanced product; positive results from the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in secondary resistance after checkpoint inhibitor failure. Other Phase 2 trials, sponsored by clinical oncology groups, of Tedopi® in combination are ongoing in solid tumors; - OSE-279 (anti-PD1): ongoing Phase 1/2 in solid tumors or lymphomas (first patient included). OSE-279 is the backbone therapy of the BiCKI® platfor; - OSE-127 - lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor); ongoing Phase 2 in Ulcerative Colitis (sponsor OSE Immunotherapeutics); ongoing preclinical research in leukemia (OSE Immunotherapeutics); - FR-104/VEL-101 (anti-CD28 monoclonal antibody): developed in partnership with Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1/2 in renal transplant (sponsor Nantes University Hospital); Phase 1 ongoing in the US (sponsor Veloxis Pharmaceuticals, Inc.); - OSE-172/BI 765063 (anti-SIRP? monoclonal antibody on CD47/SIRP? pathway) developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Phase 1 dose escalation results in monotherapy and in combination, in particular with anti-PD-1 antibody ezabenlimab; international Phase 1b ongoing clinical trial in combination with ezabenlimab alone or with other drugs in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and hepatocellular carcinoma (HCC). OSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapies: - BiCKI® platform focused on immuno-oncology (IO) is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. BiCKI-IL-7 is the most advanced BiCKI® candidate targeting anti-PD1xIL-7; - Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO and immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb) is the most advanced candidate generated by the platform, with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.87 EUR
Average target price
7.15 EUR
Spread / Average Target
+46.82%
Consensus
  1. Stock
  2. Equities
  3. Stock OSE Immunotherapeutics - Euronext Paris